Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Grossmann

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Melanoma Management|August 1, 2017
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversyMariah M Johnson, Sancy A Leachman, Lisa G Aspinwall, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Melanoma Management|August 1, 2017
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversyMariah M Johnson, Sancy A Leachman, Lisa G Aspinwall, et al.
Pageof 8